EAM
HUMA icon

Eukles Asset Management’s Humacyte HUMA Stock Holding History

Eukles Asset Management’s Portfolio HUMA Stock Details HUMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.12K Hold
4,000
– – ﹤0.01% 184
2026
Q1 		$2.43K Hold
4,000
– – ﹤0.01% 190
2025
Q4 		$3.84K Hold
4,000
– – ﹤0.01% 188
2025
Q3 		$6.96K Hold
4,000
– – ﹤0.01% 172
2025
Q2 		$8.36K Buy
4,000
+3,000
+300% +$5.76K ﹤0.01% 163
2025
Q1 		$1.71K Hold
1,000
– – ﹤0.01% 192
2024
Q4 		$5.05K Hold
1,000
– – ﹤0.01% 174
2024
Q3 		$5.44K Hold
1,000
– – ﹤0.01% 177
2024
Q2 		$4.8K Buy
+1,000
New +$5.21K ﹤0.01% 180

Other funds holding HUMA

AP
Antipodes Partners Royal Exchange, Australia $5.46B AUM 26.64% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
DKCM
Davidson Kempner Capital Management New York $8.42B AUM 61.81% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Eukles Asset Management's HUMA Position: Q2 2026 in Review

Eukles Asset Management held its Humacyte (HUMA) position steady in Q2 2026 at 4,000 shares worth $3.12K. The position accounts for ﹤0.01% of the portfolio, ranked #184.

Eukles Asset Management first reported a position in HUMA in Q2 2024 and has held it in 9 quarters since. The position peaked at $8.36K in Q2 2025. 164 funds tracked by Wall St. Rank hold HUMA as of Q2 2026.

  • Eukles Asset Management held 4,000 shares of Humacyte worth $3.12K as of Q2 2026.
  • Eukles Asset Management left its Humacyte share count unchanged in Q2 2026.
  • Humacyte made up ﹤0.01% of Eukles Asset Management's portfolio in Q2 2026, its #184 holding.
  • Eukles Asset Management first reported a position in Humacyte in Q2 2024 and has held it in 9 quarters since.
  • Eukles Asset Management's Humacyte position peaked at $8.36K in Q2 2025.
  • 164 funds tracked by Wall St. Rank held Humacyte as of Q2 2026.

Based on Eukles Asset Management's 13F filing for Q2 2026, filed 5 Aug 2026.